Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options.
Check out the year in review, more information on the HVTN 505 vaccine trial, ongoing efficacy trial updates and PrEP in 2009 preview--download now!
-------------------------------------------------------------------------------------------------------------------------
STEP data published in the Lancet
The Lancet recently published several pieces on data from the STEP vaccine trial. AVAC has developed a reader's guide to this set of articles that can be accessed here:
An Advocates’ Guide to Recent Publications on the STEP AIDS Vaccine Trial Data
-------------------------------------------------------------------------------------------------------------------------
AVAC Reports on AIDS Vaccine 08 conference
AIDS Vaccine 2008, the annual gathering held to discuss developments in the field, took place in Cape Town 13-16 October. This was the first AIDS Vaccine Conference held in Africa and also the first one since the results of the STEP and Phambili vaccine trials shook the field just over a year ago...
**Click here to read the full report**
-------------------------------------------------------------------------------------------------------------------------
HVTN 505 vaccine trial update and teleconferences
Click here to read AVAC's recent Advocates' Network update on HVTN 505
-------------------------------------------------------------------------------------------------------------------------
Cutting through the news: Understanding recent reports on male circumcision
Click here for AVAC's coverage of recent news stories and scientific publications about male circumcision for HIV prevention including information on what's known--and what remains unknown--about the relationship between circumcision status and risk of HIV infection in gay men and other men who have sex with men (MSM).
-------------------------------------------------------------------------------------------------------------------------
PrEP Advocacy Update
Over the past several months AVAC and its partners have been ramping up efforts to expand the pre-exposure prophylaxis (PrEP) for HIV prevention agenda. Activities include a new report on the state of PrEP research and advocacy priorities for the months ahead, and a dynamic satellite session on PrEP that took place in Mexico City at the International AIDS Conference. Click the links below for more:
Download the meeting report from AVAC's satellite session, "Expecting (and managing) the unexpected: Reality check for PrEP and other new prevention options"
Download AVAC's new report on PrEP (pre-exposure prophylaxis), "Anticipating the Results of PrEP Trials: A powerful new HIV prevention tool may be on the horizon. Are we prepared?"
Download AVAC's recent Advocates' Network update on PrEP
-------------------------------------------------------------------------------------------------------------------------
AVAC's publications and continuous policy, advocacy, education and outreach work is made possible by the dedicated labor of AVAC advocates and support from Broadway Cares/Equity Fights AIDS, the Ford Foundation, the Bill &
Melinda Gates Foundation, the Global HIV Vaccine Enterprise, the International AIDS Vaccine Initiative, the International Partnership for Microbicides, Until There's a Cure Foundation®, the WHO-UNAIDS HIV Vaccine Initiative, UNAIDS, and many generous individuals who have become AVAC Members.
